3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neoplasm Metastasis
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Camurati-Engelmann Syndrome
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Melanoma
2
Head and Neck Neoplasms
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Tertiary Lymphoid Structures
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Interventions
Injections
2
Infusions, Intravenous
2
tislelizumab
1
sacituzumab govitecan
1
bintrafusp alfa protein, human
1
avelumab
1
Tomography, X-Ray Computed
1
Platinum
1
Nivolumab
1
Ipilimumab
1
Iodine-125
1
Gemcitabine
1
FANG vaccine
1
Electrocardiography
1
Echocardiography
1
DOXO-EMCH
1
Cetuximab
1
Cell- and Tissue-Based Therapy
1
Antibodies, Bispecific
1
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Solid Tumors
×
bintrafusp alfa protein, human
×
Clear all
NCT04457778
2026-05-04
First in Human Study of M6223
EMD Serono
Phase 1
Completed
58 enrolled
38 charts